Rapt Scraps Zelnecirnon, But Not Giving Up On CCR4

The company said it does not see a development path for zelnecirnon based on feedback from the US FDA. It halted two Phase II trials in asthma and atopic dermatitis earlier this year.

Key Takeaways

Rapt Therapeutics is terminating development of its lead drug, the CCR4 antagonist zelneciron, which was in development for atopic dermatitis and asthma.

Rapt Therapeutics does not see a development path for its lead drug candidate zelneciron (RPT193), so it is terminating development...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Spyre Takes Aim At Roche And J&J In Inflammatory Diseases

18 Jun 2025

• By Andrew McConaghie

The US firm was already looking to compete in ulcerative colitis, but now expands its ambitions by moving into rheumatoid arthritis as well.

UCB Follows Fellow European Pharmas With Major US Investment

13 Jun 2025

• By Kevin Grogan

The Belgian drugmaker is boosting its biologics capacity over the pond.

Sanofi Revels In More Positive Rilzabrutinib Data

12 Jun 2025

• By Kevin Grogan

The oral BTK inhibitor impresses in a Phase II trial for IgG4-related disease.

How AstraZeneca Aims To Stay Ahead In Lupus As New Competition Looms

12 Jun 2025

• By Andrew McConaghie

The company has established the efficacy of its biologic Saphenlo in systemic lupus erythematosus but is now investing across modalities to stay ahead of rivals.